Table 1.
Relative difference in erythrocyte protoporphyrin and serum iron levels for study completers.
*Stopped study drug early due to primary safety endpoint being met (35% increase in ePPIX over baseline).
Green indicates an improvement in levels from baseline to end of study.
#Month 12 serum iron testing not done due to sample error.
$Discontinued iron due to increased EPP symptoms.
